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Background. Platelet function analysis utilizing platelet-rich plasma and optical density based aggregometry fails to identify patients
at risk for uremia associated complications.Methods. We employed whole blood platelet aggregation analysis based on impedance
as well as determination of ATP release from platelet granules detected by a chemiluminescence method. Ten chronic kidney
disease (CKD) stage 4 or 5 predialysis patients underwent platelet evaluation. Our study aims to evaluate this platform in this
patient population to determine if abnormalities could be detected. Results. Analysis revealed normal aggregation and ATP release
to collagen, ADP, and high-dose ristocetin. ATP release had a low response to arachidonic acid (0.37 ± 0.26 nmoles, reference
range: 0.6–1.4 nmoles). Platelet aggregation to low-dose ristocetin revealed an exaggerated response (20.9 ± 18.7 ohms, reference
range: 0–5 ohms). Conclusions. Whole blood platelet analysis detected platelet dysfunction which may be associated with bleeding
and thrombotic risks in uremia. Diminished ATP release to arachidonic acid (an aspirin-like defect) in uremic patients may result
in platelet associated bleeding. An increased aggregation response to low-dose ristocetin (a type IIb von Willebrand disease-like
defect) is associated with thrombus formation. This platelet hyperreactivity may be associated with a thrombotic diathesis as seen
in some uremic patients.
1. Introduction
Bleeding and thrombosis occur frequently in patients with
renal insufficiency and uremia [1–3]. Uremic patients sched-
uled for surgery or invasive procedures would benefit from
early identification for bleeding and/or thromboses risks.
Multiple etiologies contribute to the pathogenesis of ure-
mic bleeding. Proposed mechanisms include platelet storage
pool deficiency, abnormal platelet metabolism, endothelial
cell changes, increased cyclic adenosine monophosphate
(cAMP), abnormal platelet binding to von Willebrand factor
(vWF), effects of anemia, and fibrinogen impairment [4–9].
In response to thrombin, secretory mechanisms of ATP and
other granule contents are suggested to be diminished in
uremia [10, 11]. Mechanisms of thrombotic diathesis include
enhanced platelet aggregation, an impaired fibrinolytic sys-
tem, increased surface exposure of phosphatidylserine and
increased fibrinogen, factor 8, and vWF activity [12]. Abnor-
mal platelet function has not been attributable to high
concentrations of urea alone, suggesting unique conditions
of renal failure associated uremia [13].
Platelet aggregometry has been used to determine the
presence of platelet dysfunction in patients with chronic
renal failure (CRF) at risk for bleeding or thrombosis.
The conventional optical assessment of platelet aggregation
by Born is technically demanding, expensive and requires
platelet-rich plasma (PRP) [14]. The centrifugation steps
needed to make PRP can damage platelets and artificially
separate platelets from other in vivo plasma factors [15, 16].
Results involving PRP are conflicting, and platelet responses
are variable to different stimuli. Thrombotic diathesis cannot
be clearly demonstrated with this assay.
Measuring aggregation by impedance in a newer method
[17] uses whole blood and has several advantages with con-
ventional platelet aggregometry [18]. Whole blood samples
take less processing time. In addition, since red and white
blood cells both affect platelet aggregation, this assay repli-
cates in vivo conditionsmore closely.Thewhole blood sample
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preserves labile factors that also affect platelet functioning
in uremia, such as thromboxane A2 and prostacyclin [19].
The addition of chemiluminescence technologies allows for
simultaneous monitoring of ATP release to various agonists.
Demonstration of ATP release reflects intact signal trans-
duction pathways including cyclooxygenase function and
thromboxane A2 generation.
This study determines whether a specific pattern of
platelet dysfunction could be seen using whole blood impe-
dance based platelet aggregometry with monitoring of ATP
release. We hypothesize that patients with high-stage CKD
will have abnormal measurements of whole blood platelet
aggregation and ATP secretion given the derangements of
uremia on platelets in these patients.
2. Materials and Methods
The George Washington University Institutional Review
Board approved this study, and the experiment was con-
ducted with the understanding and the consent of the human
subjects. Nephrologists identified eligible subjects from the
clinic at the George Washington University, Medical Faculty
Associates (MFA) or the GeorgeWashingtonUniversity Hos-
pital (GWUH). The inclusion criteria for consented subjects
were CKD stage 5 not on dialysis (estimated glomerular
filtration rate (eGFR) < 15mL/min per 1.73m2) or CKD Stage
4 (GFR = 15–29mL/min) as defined by the National Kidney
Foundation practice guidelines [20]. Subjects’ blood samples
were obtained prior to the initiation of dialysis, thus avoiding
any confounding effects of partially treated uremia (residual
syndrome). Exclusion criteria included patients who had
taken any medications within the preceding two weeks that
may affect platelet function, such as aspirin, other nons-
teroidal inflammatory drugs, thienopyridines, glycoprotein
IIb/IIIa receptor antagonists, dipyridamole, and penicillins
[21].
The MFA and/or GWUH medical record provided the
subjects’ demographics, medical history, medication list,
eGFR, serum creatinine, urinalysis, blood urea nitrogen
(BUN), hemoglobin, hematocrit, and platelet count.
A single venipuncture obtained approximately ten
milliliters of blood from each enrolled subject using
standard protocol. The venipuncture was performed by
an experienced phlebotomist either in the phlebotomy
lab sponsored by the MFA or at the subject’s bedside at
GWUH. Samples were collected in five to seven plastic
tubes containing sodium citrate 3.2%. Clot-free samples
remained at room temperature and were transported
directly to the GWUH’s clinical pathology laboratory and
analyzed within 2 hours from collection on a Chrono-Log
Model 700 Whole Blood/Optical Lumi-Aggregometer using
Aggro/Link8 windows software (Chrono-Log Corporation,
Havertown, PA 19083, USA). The aggregometer measured
both platelet aggregation and ATP release. The laboratory
used standardized protocols and instructions provided by
the manufacturer.
The aggregometer measured platelet aggregation as a
function of percent electrical impedance (ohms). Briefly, the
process consists of immersing an electrode in the blood
sample onto which platelets attach uniformly in a monolayer.
Once an agonist is added, platelet clumps form on the
electrode and thus affect the impedance across it in a mea-
sureable way.The platelet agonist reagents (Chrono-Log Cor-
poration, Havertown, PA, USA) included collagen (2 𝜇g/mL
and 5 𝜇g/mL), arachidonic acid (AA, 0.5mM), adenosine
diphosphate (ADP, 10 𝜇M), and ristocetin (0.25mg/mL and
1.25mg/mL).
During the same analysis, samples were measured for
the ATP release reaction from platelet dense granules. A
high-gain photomultiplier tube recorded the binding of
platelet secreted ATP to an added firefly luciferin luciferase
(chromolume, Chrono-Log Corporation). This emitted light
was thus proportional to the secretedATP (nmoles) following
the addition of platelet agonist reagents (Chrono-log Cor-
poration, Havertown, PA 19083, USA), including thrombin
(1 unit), collagen, AA, and ADP. The latter three agonists
were at the same concentration as that used for the platelet
aggregation phase of testing.
Results were correlated to the clinical data and compared
to reference ranges. These reference ranges were established
in house by the GWUH Pathology Laboratory [16, 22]
and obtained by evaluating twenty healthy volunteers with
no clinical or laboratory evidence of renal disease. Each
reference range represents the interval that is 95% of values
from control groups of healthy volunteers. Data on each study
participant for each platelet agonist was expressed as a mean
± 1 standard deviation.
Informed consent for all participants in this study was
obtained, and the study adhered to the provisions of the
Declaration of Helsinki.
3. Results
A total of ten subjects meeting inclusion criteria were ana-
lyzed.
Table 1 summarizes subject characteristics. The subjects’
ages range from 39 to 79 years old.
Tables 2 and 3 describe the results of the study. As seen
in Table 2, the mean values for platelet aggregation responses
to collagen (2 𝜇g/mL and 5𝜇g/mL), AA, ADP, and high
dose ristocetin (1.25mg/mL) fall within the normal reference
range. As noted in Table 2, and illustrated in Figure 1, platelet
aggregation to low-dose ristocetin (0.25mg/mL) reached
approximately four times the limit of the upper range (mean
of 20.9 ohms versus 5 ohms for the upper limit of normal).
As seen in Table 3, the mean values for ATP release to
thrombin, low- and high-dose collagen, and ADP remained
in the normal reference range. As noted in Table 3 and
illustrated in Figure 2, platelet ATP release to the agonist
AA was below the lower limit of the normal reference range
(0.37 nmoles versus 0.6 nmoles for the lower limit of the
normal reference range).
4. Discussion
Our lab has recently acquired whole blood platelet aggre-
gation technology that can simultaneously test both platelet
aggregation and the ATP release reaction. We evaluated both
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Table 1: Characteristics of study subjects.
Patient Age Gender CKD CR BUN eGFR HGB HCT PLT
1 61 M 4 3.36 55 23 9.8 30 239
2 56 M 4 3.44 58 22 9.9 30 195
3 54 F 5 10.1 77 5 8.7 26.9 275
4 39 F 5 8.61 75 6 10.5 34.3 444
5 79 M 4 3.65 46 20 10.1 30.4 330
6 66 F 5 12.15 92 3 5.4 16.6 205
7 69 F 5 8.3 52 4 9.2 26.8 203
8 52 M 5 6.04 32 11 13.2 39.9 274
9 61 F 5 4.15 51 13 8.7 27.1 269
10 46 F 5 15 94 3 9.4 27.9 241
Mean ± Std dev 58 ± 11.6 7.48 ± 4.06 63 ± 20 11 ± 8 9.5 ± 1.93 29.0 ± 5.95 268 ± 74.5
CKD: chronic kidney disease stage, CR: serum creatinine; BUN: blood urea nitrogen, eGFR: estimated glomerular filtration rate, HGB: hemoglobin, HCT:
hematocrit, and PLT: platelets. Reference ranges: CR: 0.76–1.27mg/dL; BUN: 5–26mg/dL; eGFR> 59mL/min/1.73; HGB: 12.5–17.0 g/dL, HCT: 36.0–50.0%,
and PLT: 140–415 × 103/𝜇L.
Table 2: Results of platelet aggregometry (values expressed in ohms).
Patient Collagen 2𝜇g/mL Collagen 5 𝜇g/mL AA 0.5mM ADP 10 𝜇M Ristocetin 0.25mg/mL Ristocetin 1.25mg/mL
1 0 28 0 24 10 46
2 28 26 14 22 7 46
3 27 26 15 22 23 44
4 19 41 34 28 47 47
5 30 33 30 26 46 45
6 24 30 21 19 46 30
7 6 12 0 21 4 8
8 10 15 0 29 18 28
9 7 13 3 28 6 28
10 12 19 6 5 2 25
Mean ± Std dev 16.3 ± 10.7 24.3 ± 9.43 12.3 ± 12.7 22.4 ± 6.98 20.9 ± 18.7 34.7 ± 13.0
Ref 15–27 15–31 5-17 6–24 0–5 >5
AA: arachidonic acid and ADP: adenosine diphosphate.
Table 3: Results of platelet ATP release reaction (values expressed in nmoles).
Patient Thrombin 1U Collagen 2 𝜇g/mL Collagen 5 𝜇g/mL AA 0.5mM ADP 10 𝜇M
1 0.89 1.06 2.05 0.53 0.18
2 0.9 0.79 0.88 0.29 0.16
3 3.63 3.06 3.74 0.69 1.49
4 1.21 1.52 1.24 0.53 0.37
5 1.55 1.8 1.56 0.77 0.4
6 3.5 0.22 0.18 0 0.7
7 0.82 0.41 0.73 0 3
8 1.15 0.52 0.83 0.2 0.64
9 0.9 0.62 0.63 0.36 1.47
10 0.93 0.26 0.67 0.29 0.14
Mean ± Std dev 1.55 ± 1.09 1.03 ± 0.89 1.25 ± 1.02 0.37 ± 0.26 0.86 ± 0.90
Ref >0.5 0.5–1.7 0.9–1.7 0.6–1.4 0.38–1.71
AA: arachidonic acid and ADP: adenosine diphosphate.
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Figure 1: Graphical results of platelet aggregometry to ristocetin
0.25mg/mL. Dashed line represents the bound of normal reference
range (0–5 ohms). Eight of ten patients demonstrate aggregation
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Figure 2: Graphical results of platelet ATP release to arachidonic
acid 0.5mM. Dashed lines represent bounds of normal reference
range (0.6–1.4 nmoles). Eight of ten patients demonstrate lower than
normal ATP release to the agonist arachidonic acid.
of these parameters in uremic patients with CKD stage 4
or 5 just prior to each patient starting hemodialysis. The
current literature supports platelet dysfunction in uremia
being a cause for bleeding and/or thrombosis, but the nature
of the dysfunction has yet to be clearly elucidated. This study
further contributes to the understanding of the effects ofCKD
associated uremia on platelet function.
Use of platelet-rich plasma (PRP) traditionally helped to
describe bleeding tendencies in uremia, but has limitations
in illustrating thrombotic diathesis. This study avoids PRP
as the aggregation substrate because of inconsistencies with
methodology and reproducibility [17, 18, 23–25]. Whole
blood from simple venipuncture provides a quick, relatively
inexpensive means of attaining platelet aggregation and ATP
secretion data from a sample that relates more closely to in
vivo conditions.
Some authors suggest whole blood platelet aggregation
in uremia to be normal as compared to controls [24].
Other authors have found aggregation to be decreased [7]
or increased [10, 26]. The preponderance of the conflict-
ing results in the literature comes from studies that have
examined uremic platelet aggregation using the less accurate
PRP based opticalmethods. Furthermore, the chronic kidney
disease subjects evaluated in these studies had already started
on chronic dialysis. Our study examines whole blood of
patients prior to the initiation of dialysis and thus avoids the
complexities of partially treated uremia in dialyzed patients
[5, 27]. Even so, the whole blood impedance based results
of our study parallel the literature with no specific trends in
aggregation results for low-dose collagen (2 𝜇g/mL), high-
dose collagen (5 𝜇g/mL), or ADP. It should be noted that no
one has reported a correlation between the degree of uremia
and platelet aggregation impairment [25].We also confirmno
such correlation in our study, specifically in CKD stage 4 and
stage 5 patients.
To our knowledge, no previous literature systematically
studied whole blood platelet aggregation in response to AA
or low-dose ristocetin in uremic patients. Platelet aggregation
responses to AA in our study showed varying results: 40% of
values, decreased, 30% had normal measurements and 30%
were increased. Some authors have theorized that uremic
toxins only cause defective aggregation in the high shear
forces of the vascular flow system and not within the artificial
environment of the aggregometer [4]. Others have suggested
that bleeding tendencies may not relate to aggregation at
all but more so to platelet adhesion and/or secretion [24].
Defects in cyclooxygenase can be investigated by addition
of this enzyme’s substrate, AA. Eighty percent of the uremic
patients in our study showed low levels of ATP release in
response to the AA agonist. Free arachidonic acid is con-
verted by cyclooxygenase to prostaglandinsG2 andH2.These
prostaglandins are then converted by thromboxane synthase
to thromboxane A2.This latter molecule promotes additional
platelet activation andplatelet aggregationwith dense granule
release of ATP. Our results suggest that there is inhibition
of this cyclooxygenase pathway. Indeed the findings simulate
an aspirin-like effect. The literature has suggested defective
prostaglandin synthesis in uremic platelets involving the
cyclooxygenase pathway as implied by decreased generation
of thromboxane A2 in response to addition of AA, ADP,
thrombin, and collagen [19, 28]. Curiously, thromboxane A2
levels normalize or even increase in patients after initiating
dialysis [29, 30]. Our study provides evidence that uremia
diminishes cyclooxygenase activity.
Defects of ATP release in uremic platelet dysfunction
parallel observations in inherited platelet function disorders,
even with normal aggregation results [31]. Pai et al. found
more commonly reduced platelet ATP release in response to
one or more agonists in patients with bleeding disorders as
compared to healthy control subjects [31]. Of note, relatively
mild platelet abnormalities alter in vitro aggregation studies,
which may not be prognostic of actual bleeding risk [32, 33].
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Our study documents an aspirin-like defect as a likely factor
contributing to a bleeding diathesis seen in CKD patients.
This finding was evident based on ATP release to AA. In fact,
impairment of the cyclooxygenase pathway would not have
been detected in 60% of the patients if it is based only on
platelet aggregation responses to AA.
Interestingly, 80% of the patients in our study had
increased platelet aggregation to low-dose ristocetin (0.25
mg/mL). This differs from reported whole blood based data
from Ho et al., where the minority of the uremic patients in
their study had impaired ristocetin impedance [25].However,
this study investigated patients already on dialysis and many
patients concomitantly on antiplatelet therapy.
Uremic patients may have a simultaneous risk factor for
hypercoagulability as suggested by an exaggerated platelet
aggregation response to low-dose ristocetin. This latter find-
ing resembles that seen in type IIb von Willebrand disease
and the platelet type of vonWillebrand disease.These patients
may also have a predisposition to thrombus formation. Test-
ing with high-dose ristocetin cannot detect patients with a
potential thrombotic diathesis; therefore, low-dose ristocetin
should be employed in patients at risk for hypercoagulability
as in uremia.
Whole blood platelet aggregation analysis with measure-
ment of ATP release can be used to identify uremic patients
who may be at risk for platelet based bleeding or thrombotic
complications.Additional studies should focus on elucidating
themechanisms of our study’s findings in an attempt to better
determine both a diagnostic approach and the appropriate
selection of therapeutic agents in uremic patients with either
bleeding and/or hypercoagulability.
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